India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports

Cipla

22/07/2026 09:20

Updates
** Nifty Pharma Index .NIPHARM down 1.52%
** Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS, Cipla CIPL.NS, Lupin LUPN.NS, Glenmark GLEN.NS, Dr Reddy's REDY.NS and Zydus ZYDU.NS decline 1.2%-3.9%, with Lupin the worst hit
** Trump says imported generic drugs will remain tariff-free for two years from August 1, before tariffs increase to 100% for one year and 200% thereafter
** "The headline is negative, but key details around implementation, legal challenges, exemptions and final scope remain unclear ... We would view it more as a policy signal than a quantifiable earnings event" - Niharika Agarwal, analyst at Nirmal Bang
** PL Capital says existing U.S. facilities may partly cushion impact, but two years is too short to relocate entire generic pharma value chain
** Motilal Oswal says tariff implementation remains uncertain, with major impact due from August 2028, near end of Trump's term

(Reporting by Abhinav Parmar in Bengaluru)
((Abhinav.Parmar@thomsonreuters.com;))